selenocysteine has been researched along with Angiogenesis, Pathologic in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bhattacharya, A; Oven, SD; Rustum, YM; Seshadri, M; Tóth, K; Vaughan, MM | 1 |
Belame, A; Burow, ME; Carrier, L; Li, Z; Rowan, BG; Salvo, VA; Thiyagarajah, A | 1 |
Bhattacharya, A; Cao, S; Durrani, FA; Faber, E; Repasky, EA; Rustum, YM; Sen, A; Seshadri, M; Tóth, K | 1 |
Bhattacharya, A; Hoffman, RM; Rajput, A; Rustum, YM; San Martin, ID; Seshadri, M; Turowski, SG | 1 |
Bernhard, EJ | 1 |
Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Frank, C; Hapke, G; Li, ZR; Rustum, YM; Tóth, K; Yin, MB | 1 |
1 review(s) available for selenocysteine and Angiogenesis, Pathologic
Article | Year |
---|---|
Interventions that induce modifications in the tumor microenvironment.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Adhesion; Cell Hypoxia; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cysteine; Cytotoxins; Drug Screening Assays, Antitumor; Extracellular Matrix; Genetic Therapy; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Neoplastic Stem Cells; Neovascularization, Pathologic; Organoselenium Compounds; Radiation Tolerance; Radiotherapy; Selenocysteine; Signal Transduction; Stromal Cells; Tumor Microenvironment | 2011 |
5 other study(ies) available for selenocysteine and Angiogenesis, Pathologic
Article | Year |
---|---|
Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeability; Carcinoma, Squamous Cell; Cysteine; Drug Delivery Systems; Drug Synergism; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Organoselenium Compounds; Selenocysteine; Xenograft Model Antitumor Assays | 2008 |
Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Division; Cyclin D1; Cysteine; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Organoselenium Compounds; Random Allocation; Receptors, Progesterone; Selenocysteine; Specific Pathogen-Free Organisms; Tamoxifen; Xenograft Model Antitumor Assays | 2009 |
Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.
Topics: Animals; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Cell Differentiation; Colon; Colorectal Neoplasms; Cysteine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Hypoxia; Immunoenzyme Techniques; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Organoselenium Compounds; Selenocysteine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cysteine; Diagnostic Imaging; Female; Green Fluorescent Proteins; Humans; Magnetic Resonance Imaging; Mice; Mice, Nude; Microvessels; Neovascularization, Pathologic; Organoselenium Compounds; Random Allocation; Selenocysteine; Xenograft Model Antitumor Assays | 2011 |
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiog
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cysteine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Organoselenium Compounds; Selenocysteine; Transplantation, Heterologous | 2006 |